Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Study Drug (“BMS Study Data”), and the Recipient shall own the Study Data to the extent that it relates exclusively to the Recipient Study Drug (“Recipient Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the Recipient Study Drug or the BMS Study Drug (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.
Appears in 6 contracts
Samples: Clinical Trial Collaboration and Supply Agreement (Replimune Group, Inc.), Clinical Trial Collaboration and Supply Agreement (Idera Pharmaceuticals, Inc.), Clinical Trial Collaboration and Supply Agreement (Idera Pharmaceuticals, Inc.)
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Study Drug Compound (“BMS Study Data”), and the Recipient Five Prime shall own the Study Data to the extent that it relates exclusively to the Recipient Study Drug Five Prime Compound (“Recipient Five Prime Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the Recipient Study Drug Five Prime Compound or the BMS Study Drug Compound (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.
Appears in 1 contract
Samples: Clinical Trial Collaboration Agreement (Five Prime Therapeutics Inc)
Ownership of Study Data. BMS shall own the Study Data to the extent that it relates exclusively to the BMS Study Drug Compound (“BMS Study Data”), and the Recipient Nektar shall own the Study Data to the extent that it relates exclusively to the Recipient Study Drug Nektar Compound (“Recipient Nektar Study Data”). Both Parties shall jointly own any Study Data that does not relate exclusively to the Recipient Study Drug Nektar Compound or the BMS Study Drug Compound (“Combined Therapy Study Data”). Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Study Data as is necessary to fully effect the foregoing, and agrees to execute all instruments as may be reasonably necessary to effect same.
Appears in 1 contract
Samples: Clinical Trial Collaboration Agreement (Nektar Therapeutics)
